Literature DB >> 3081644

A feline thymocyte antigen defined by a monoclonal antibody (FT2) identifies a subpopulation of non-helper cells capable of specific cytotoxicity.

F W Klotz, M D Cooper.   

Abstract

A monoclonal antibody, FT2 (IgG1 kappa) prepared against cat thymocytes, was found to be reactive with an antigenic determinant expressed by approximately 76% of thymocytes, 15% of blood mononuclear cells, 14% of splenocytes, and 1% of bone marrow cells. The FT2-reactive determinant was not expressed on B cells, macrophages, granulocytes, or erythrocytes. Both FT2+ and FT2- populations of peripheral blood mononuclear cells were capable of proliferative responses to the T cell mitogens Con A and PHA. When splenocytes were sensitized to the lymphoblastoid cell line, 79p90, cytotoxic T cells were found in the FT2+ population and were absent from the FT2- population. Conversely, the FT2- population contained the helper T cell activity required for pokeweed mitogen-induced B cell differentiation. Under nonreducing conditions, the FT2 antigen had an apparent m.w. of 71,000. When reduced, subunits of 31,000 and 38,000 apparent m.w. were observed. The data suggest that the FT2 antibody identifies the feline analog of the human T8/Leu-2, murine Ly-2 molecules expressed by cytotoxic/suppressor T cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081644

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

2.  Isolation and characterization of three subpopulations of IgG in the common cat (Felis catus).

Authors:  C I Baldwin; D A Denham
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

3.  Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection.

Authors:  N C Pedersen; M Torten; B Rideout; E Sparger; T Tonachini; P A Luciw; C Ackley; N Levy; J Yamamoto
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  Worldwide prevalence of lentivirus infection in wild feline species: epidemiologic and phylogenetic aspects.

Authors:  R A Olmsted; R Langley; M E Roelke; R M Goeken; D Adger-Johnson; J P Goff; J P Albert; C Packer; M K Laurenson; T M Caro
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset.

Authors:  B J Willett; M J Hosie; J J Callanan; J C Neil; O Jarrett
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

6.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

7.  An early defect in primary and secondary T cell responses in asymptomatic cats during acute feline immunodeficiency virus (FIV) infection.

Authors:  S A Bishop; N A Williams; T J Gruffydd-Jones; D A Harbour; C R Stokes
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

8.  Immunological changes in cats with concurrent Toxoplasma gondii and feline immunodeficiency virus infections.

Authors:  D S Lin; D D Bowman; R H Jacobson
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

9.  Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat.

Authors:  K H Siebelink; I H Chu; G F Rimmelzwaan; K Weijer; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage.

Authors:  L J Diehl; C K Mathiason-Dubard; L L O'Neil; L A Obert; E A Hoover
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.